{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:44:21Z","timestamp":1781790261740,"version":"3.54.5"},"reference-count":20,"publisher":"Georg Thieme Verlag KG","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endoscopy"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2002Oxaliplatin, used as first-choice treatment for colorectal cancer (CRC), induces sinusoidal endothelial injury and portal hypertension. This study investigated the characteristics of oxaliplatin-induced portal hypertension and evaluated the efficacy of endoscopic management of gastroesophageal variceal bleeding.<\/jats:p><jats:p>\n          Methods\u2002We performed a retrospective, multicenter, case-control study between January 2010 and December 2018. Patients who received oxaliplatin-based chemotherapy after CRC surgery and presented with portal hypertension and gastroesophageal varices were compared with consecutive patients with hepatitis B-related cirrhotic portal hypertension receiving endoscopic treatment for variceal bleeding.<\/jats:p><jats:p>\n          Results\u200239 patients with oxaliplatin-induced portal hypertension were identified, 35 of whom had a history of variceal bleeding. The median period between start of oxaliplatin-based chemotherapy and the occurrence of varices was 50.4 months (n\u200a=\u200a39). A total of 26 patients with oxaliplatin-related portal hypertension and 230 patients with hepatitis B-related portal hypertension underwent endoscopic treatment. Kaplan-Meier analysis revealed that the 1-year rebleeding rate was significantly higher in the oxaliplatin group than in the hepatitis B group (43.3\u200a% vs. 19.0\u200a%, P\u200a=\u200a0.001). Multivariable Cox regression analysis showed that oxaliplatin-based chemotherapy was an independent factor for 3-year rebleeding (hazard ratio [HR] 2.46, 95\u200a% confidence interval [CI] 1.24\u20134.87; P\u200a=\u200a0.01) and 3-year overall mortality (HR 9.43, 95\u200a%CI 2.32\u201338.31; P\u200a=\u200a0.002).<\/jats:p><jats:p>\n          Conclusions\u2002Oxaliplatin-related portal hypertension was characterized by massive ascites, splenomegaly, gastric varices, concomitant arterioportal fistula, and relatively normal liver function. Endoscopic treatment to prevent variceal rebleeding in these patients was unsatisfactory compared with endoscopic treatment for hepatitis B-related portal hypertension.<\/jats:p>","DOI":"10.1055\/a-1157-8611","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T22:35:47Z","timestamp":1588890947000},"page":"727-735","source":"Crossref","is-referenced-by-count":11,"title":["Endoscopic treatment of gastroesophageal variceal bleeding after oxaliplatin-based chemotherapy in patients with colorectal cancer"],"prefix":"10.1055","volume":"52","author":[{"given":"Xiaoquan","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, P.R. China"},{"name":"Center of Evidence-Based Medicine, Fudan University, Shanghai, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Li","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Anhui Provincial Hospital, Hefei, Anhui, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health, Fudan University, Shanghai, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, P.R. China"},{"name":"Center of Evidence-Based Medicine, Fudan University, Shanghai, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"T Andre","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","article-title":"Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study","volume":"33","author":"T Andre","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"T Andre","year":"2004","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1200\/JCO.2006.05.8156","article-title":"Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases","volume":"24","author":"T Aloia","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2009.27.5701","article-title":"Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury","volume":"28","author":"M J Overman","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdh095","article-title":"Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer","volume":"15","author":"L Rubbia-Brandt","year":"2004","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/jso.24756","article-title":"Oxaliplatin-induced increase in splenic volume; irreversible change after adjuvant FOLFOX","volume":"116","author":"T Iwai","year":"2017","journal-title":"J Surg Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3816\/CCC.2009.n.038","article-title":"Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury","volume":"8","author":"J H Slade","year":"2009","journal-title":"Clin Colorectal Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.dld.2019.06.020","article-title":"Incidence of portal hypertension in patients exposed to oxaliplatin","volume":"51","author":"S Gioia","year":"2019","journal-title":"Dig Liver Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"R de Franchis","year":"2015","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","author":"G Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"9732039","DOI":"10.1155\/2016\/9732039","article-title":"Endoscopic approaches to the treatment of variceal hemorrhage in hemodialysis-dependent patients","volume":"2016","author":"X Huang","year":"2016","journal-title":"Gastroenterol Res Pract"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"66584","DOI":"10.18632\/oncotarget.16579","article-title":"Therapeutic evaluation of arterio-portal fistula-related gastroesophageal variceal bleeding","volume":"8","author":"X Huang","year":"2017","journal-title":"Oncotarget"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.clcc.2012.02.002","article-title":"Oxaliplatin-induced hepatoportal sclerosis, portal hypertension, and variceal bleeding successfully treated with transjugular intrahepatic portosystemic shunt","volume":"11","author":"T O Lawal","year":"2012","journal-title":"Clin Colorectal Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1200\/JCO.2008.16.1893","article-title":"Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases","volume":"26","author":"J Ward","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/SLA.0b013e31815774de","article-title":"Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy","volume":"247","author":"H Nakano","year":"2008","journal-title":"Ann Surg"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000210025","article-title":"Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer","volume":"76","author":"R Angitapalli","year":"2009","journal-title":"Oncology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1478-3231.2007.01511.x","article-title":"Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?","volume":"27","author":"C Hubert","year":"2007","journal-title":"Liver Int"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/j.1440-1746.2012.07168.x","article-title":"Hepatic hemodynamics in 24 patients with nodular regenerative hyperplasia and symptomatic portal hypertension","volume":"27","author":"J Bissonnette","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jhep.2013.04.014","article-title":"Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model","volume":"59","author":"S M Robinson","year":"2013","journal-title":"J Hepatol"}],"container-title":["Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1157-8611.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T22:31:53Z","timestamp":1598481113000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1157-8611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":20,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2020,8,26]]},"published-print":{"date-parts":[[2020,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1157-8611","relation":{},"ISSN":["0013-726X","1438-8812"],"issn-type":[{"value":"0013-726X","type":"print"},{"value":"1438-8812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,7]]}}}